Datapoint

Datapoint: AbbVie Gives Up Rights to Kaletra Amid Pandemic

March 30, 2020

AbbVie will stop enforcing global patent rights on its HIV drug, Kaletra, amid the COVID-19 pandemic. The drug has entered several clinical trials to test its performance in treating the coronavirus, and the move will greatly improve worldwide access to the drug in the event of shortages. In the U.S., Kaletra currently holds preferred formulary status for 61% of all covered lives.

AbbVie will stop enforcing global patent rights on its HIV drug, Kaletra, amid the COVID-19 pandemic. The drug has entered several clinical trials to test its performance in treating the coronavirus, and the move will greatly improve worldwide access to the drug in the event of shortages. In the U.S., Kaletra currently holds preferred formulary status for 61% of all covered lives.

SOURCE: MMIT Analytics, as of 3/25/20

Datapoint: Pandemic May Cause Large Premium Surges

March 26, 2020

A new analysis from Covered California warned that the costs associated with the coronavirus pandemic could cause premium rates to rise dramatically, as much as 40% for some plans, in 2021. The state-based exchange said the outbreak could particularly hurt exchange plans, which currently cover 10,919,681 lives, as premium surges may cause many unsubsidized enrollees to drop coverage altogether.

A new analysis from Covered California warned that the costs associated with the coronavirus pandemic could cause premium rates to rise dramatically, as much as 40% for some plans, in 2021. The state-based exchange said the outbreak could particularly hurt exchange plans, which currently cover 10,919,681 lives, as premium surges may cause many unsubsidized enrollees to drop coverage altogether.

Source: AIS’s Directory of Health Plans

Datapoint: Blue Shield of California Launches COVID-19 Triage Tool

March 25, 2020

Blue Shield of California last week said its in-network hospitals will have access to a new free tool, the “COVID-19 Screener and Emergency Response Assistant.” The digital tool, which asks patients basic questions about their current health status, will help hospitals triage potential coronavirus cases. Blue Shield of California currently serves 3,304,237 lives, with 74.3% enrolled in commercial risk-based products.

Blue Shield of California last week said its in-network hospitals will have access to a new free tool, the “COVID-19 Screener and Emergency Response Assistant.” The digital tool, which asks patients basic questions about their current health status, will help hospitals triage potential coronavirus cases. Blue Shield of California currently serves 3,304,237 lives, with 74.3% enrolled in commercial risk-based products.

Source: AIS’s Directory of Health Plans

Datapoint: Virginia Eliminates Medicaid Copays

March 24, 2020

In an effort to increase access to health care as the novel coronavirus spreads, the state of Virginia has temporarily eliminated all Medicaid copayment requirements. Virginia currently serves 1,149,850 Medicaid beneficiaries, with 96.3% enrolled in managed care plans. The state has also extended prescription refills to 90 days and expanded telehealth coverage, Gov. Ralph Northam (D) said last week.

In an effort to increase access to health care as the novel coronavirus spreads, the state of Virginia has temporarily eliminated all Medicaid copayment requirements. Virginia currently serves 1,149,850 Medicaid beneficiaries, with 96.3% enrolled in managed care plans. The state has also extended prescription refills to 90 days and expanded telehealth coverage, Gov. Ralph Northam (D) said last week.

Source: AIS’s Directory of Health Plans

Datapoint: Kevzara Enters COVID-19 Trials

March 23, 2020

Sanofi and Regeneron say they have placed their rheumatoid arthritis medication, Kevzara, into immediate clinical trials in the fight against COVID-19. The drugmakers will initially focus on Kevzara’s effect on fever and patients’ need for supplemental oxygen. For the treatment of rheumatoid arthritis, Kevzara currently holds preferred status for just 1% of covered lives, growing to 8% with prior authorization and/or step therapy.

Sanofi and Regeneron say they have placed their rheumatoid arthritis medication, Kevzara, into immediate clinical trials in the fight against COVID-19. The drugmakers will initially focus on Kevzara’s effect on fever and patients’ need for supplemental oxygen. For the treatment of rheumatoid arthritis, Kevzara currently holds preferred status for just 1% of covered lives, growing to 8% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 3/18/20

Datapoint: Florida Granted First COVID-19 Emergency Medicaid Waiver

March 19, 2020

CMS this week granted Florida a Section 1135 Medicaid waiver request to fight the impact of COVID-19, the agency’s first emergency waiver approval. The state will now be able to provide care in alternative settings, use out-of-state providers and hospitals and waive screening requirements for nursing home placement. Florida currently serves 3,988,653 million Medicaid beneficiaries, with 78.8% enrolled in managed care plans.

CMS this week granted Florida a Section 1135 Medicaid waiver request to fight the impact of COVID-19, the agency’s first emergency waiver approval. The state will now be able to provide care in alternative settings, use out-of-state providers and hospitals and waive screening requirements for nursing home placement. Florida currently serves 3,988,653 million Medicaid beneficiaries, with 78.8% enrolled in managed care plans.

Source: AIS’s Directory of Health Plans